<p>紐約，2025 年 12 月 26 日（GLOBE NEWSWIRE）-- Southpoint Capital Advisors LP（“Southpoint”）作為其擔任投資經理的某些 Southpoint 基金的代表，宣佈於 2025 年 12 月 24 日，根據證券法，處置了 Fennec Pharmaceuticals Inc.（“Fennec”）的 1,000,000 股普通股（“普通股”）的實益擁有權，約佔已發行普通股的 2.93%（按完全稀釋基礎計算）。</p>
<p>普通股的出售價格為每股 7.50 美元。</p>
<p>Southpoint 目前對總計 270 萬股普通股行使控制或指揮權，約佔已發行普通股的 8%（按完全稀釋基礎計算）。</p>
<p>Southpoint 處置普通股是出於投資目的。根據市場和其他條件，Southpoint 可能會通過市場交易、私人協議、國庫發行、行使認股權證或其他方式改變其對普通股的實益擁有權或控制或指揮權。</p>
<p>本新聞稿的發佈是為了遵守適用的證券立法。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png"/></p>
<pre><code> 如需更多信息：Anthony J. Buffalano III
Southpoint Capital Advisors LP
1114 Avenue of the Americas, 22 樓
 紐約，NY 10036
 電話：（212）692-6356
</code></pre>

FENC

<p>Southpoint Capital Advisors LP 宣佈以每股 7.50 美元出售 1,000,000 股 Fennec Pharmaceuticals Inc. 的普通股，持股比例降至 8%。此次出售是出於投資目的，Southpoint 可能會根據市場情況調整其持股</p>

<p>NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025, pursuant to securities laws, it disposed of beneficial ownership of 1,000,000 common shares (a “Common Share”) of Fennec Pharmaceuticals Inc. (“Fennec”), representing approximately 2.93% of the outstanding Common Shares (calculated on a fully diluted basis).</p>
<div class="lb-trans"><p>紐約，2025 年 12 月 26 日（GLOBE NEWSWIRE）-- Southpoint Capital Advisors LP（“Southpoint”）作為其擔任投資經理的某些 Southpoint 基金的代表，宣佈於 2025 年 12 月 24 日，根據證券法，處置了 Fennec Pharmaceuticals Inc.（“Fennec”）的 1,000,000 股普通股（“普通股”）的實益擁有權，約佔已發行普通股的 2.93%（按完全稀釋基礎計算）。</p>
</div><p>The Common Shares were sold at a price of USD$7.50 per Common Share.</p>
<div class="lb-trans"><p>普通股的出售價格為每股 7.50 美元。</p>
</div><p>Southpoint now exercises control or direction over an aggregate of 2.7 million Common Shares, and representing approximately 8% of the outstanding Common Shares (calculated on a fully diluted basis).</p>
<div class="lb-trans"><p>Southpoint 目前對總計 270 萬股普通股行使控制或指揮權，約佔已發行普通股的 8%（按完全稀釋基礎計算）。</p>
</div><p>Southpoint has disposed of the Common Shares for investment purposes. Depending on market and other conditions, Southpoint may change its beneficial ownership of, or control or direction over, Common Shares through market transactions, private agreements, treasury issuances, exercise of the Warrants or otherwise.</p>
<div class="lb-trans"><p>Southpoint 處置普通股是出於投資目的。根據市場和其他條件，Southpoint 可能會通過市場交易、私人協議、國庫發行、行使認股權證或其他方式改變其對普通股的實益擁有權或控制或指揮權。</p>
</div><p>This press release has been issued in order to comply with applicable securities legislation.</p>
<div class="lb-trans"><p>本新聞稿的發佈是為了遵守適用的證券立法。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE56UXdOaU0zTXpNM01UWXpJekl3T0RrNE5URT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNzQwNiM3MzM3MTYzIzIwODk4NTE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MmQ5MWJkMjEtMDI0Zi00OGI2LWJlMmEtZDY4Y2I0MmZhMjE4LTExMDE0MjItMjAyNS0xMi0yNi1lbg==/tiny/Fennec-Pharmaceuticals-Inc-.png"/></p>
<pre><code>For further information: Anthony J. Buffalano IIISouthpoint Capital Advisors LP1114 Avenue of the Americas, 22nd FloorNew York, NY 10036Phone: (212) 692-6356
</code></pre>
<div class="lb-trans"><pre><code> 如需更多信息：Anthony J. Buffalano III
Southpoint Capital Advisors LP
1114 Avenue of the Americas, 22 樓
 紐約，NY 10036
 電話：（212）692-6356
</code></pre>
</div>

Southpoint 在 Fennec Pharmaceuticals Inc.（TSX: FENC）的持股情況 | FENC 股票新聞